• XNK Therapeutics completes building phase of new GMP facility

  • XNK Therapeutics to use generic name evencaleucel for lead candidate

  • New Position Paper: Characteristics & Positioning of Autologous NK Cell Therapies in Relation to Allogeneic Ditto

XNK Therapeutics

Individualized NK Cell Therapies

XNK Therapeutics is a clinical-stage biotechnology company developing unique and individualized natural killer (NK) cell-based cancer therapies. The R&D pipeline targets areas of high unmet medical need within both hematological malignancies and solid tumors. The most advanced product candidate, evencaleucel, is being evaluated in a phase II clinical study in combination with the CD38 monoclonal antibody isatuximab, as consolidation therapy following stem cell transplantation in newly diagnosed multiple myeloma patients.

At the core of XNK is a committed and experienced team that includes world-renowned NK cell experts and pioneers in the field. The company has developed a proprietary technology platform of broad utility and benefits from its tailor-made GMP facility and co-location with the Karolinska Institute and the Karolinska University Hospital. XNK is well positioned to bring transformational autologous NK cell-based therapies and new hope to cancer patients around the world.

CEO Quarterly Statement

It has been another busy quarter for XNK. Following the previous period when we raised SEK 132 million from existing and new investors, led by Flerie Invest AB, and continued to expand our pipeline, we didn’t slow down. Our focus is to drive our pipeline forward and ensure that we have the key talent and tools needed to benefit from the rising interest in natural killer (NK) cell therapies to treat cancer.